Investigator-Initiated Research

We measure ourselves by the impact we have on people with cancer.
Let’s continue
to innovate.

SpringWorks is committed to supporting Investigator-Initiated Research (IIR) to advance medical and scientific knowledge relating to its product candidates and current therapeutic areas of interest.

Let’s learn together.

SpringWorks will consider unsolicited research proposals submitted electronically† by external investigators interested in studying SpringWorks products or product candidates in therapeutic areas of interest.

SpringWorks will consider research proposals for clinical, preclinical, and non-interventional/observational studies as part of this program.

SpringWorks receives many requests for research support. Research support decisions are based on a careful evaluation of the scientific rigor of the research proposal, the expertise and experience of the investigator, the feasibility of supporting the research and the strategic interest of SpringWorks.

Interested investigators may submit research proposals in our strategic areas of interest by visiting: https://startone.vibrantm.com. By clicking on this link you will be redirected to a new webpage, as Springworks Therapeutics is now a healthcare company of Merck KGaA, Darmstadt, Germany.

Desmoid tumor

  • Combination treatment (excluding radiation)
  • Pathogenesis and management of adverse events
  • Symptomatic desmoid tumor without radiologic progression
  • Treatment duration
  • Adjuvant approach
  • Drug holiday/rechallenge

Non-desmoid tumor

  • Monotherapy and rational combinations with other therapies in solid tumors

Neurofibromatosis type 1 (NF1) plexiform neurofibroma (PN)

  • Neoadjuvant/adjuvant therapy
  • Combination therapies for NF1-PN
  • PN growth and treatment-related biomarkers
  • Spinal PNs
  • Efficacy following prior MEKi therapy failure and MEKi sequencing
  • Mechanism of resistance
  • PN-related morbidity prevention

Other NF1 manifestations

  • Combination therapies for malignant peripheral nerve sheath tumors
  • Neurocognitive deficits
  • Skeletal manifestations
  • Pain control

Other tumor types

  • Combination therapies for high grade glioma
  • RASopathies
  • NF2-associated and sporadic schwannoma
  • Combination therapies for sarcoma
  • Combination therapies for TSC1 and TSC2 associated tumors
  • Combination therapies for acute myeloid leukemia with overactive MAPK signaling

†SpringWorks shall have no obligation to maintain the confidentiality of submitted research proposals and documents. This statement shall not supersede or otherwise affect the terms of any existing agreements between SpringWorks and the institution/investigator on whose behalf a research proposal is being submitted.